Xequel Bio
Research - Fort Worth, Texas, United States
Xequel Bio Details
Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body's response to injury.aCT1 is a patented new chemical entity currently in development for multiple indications. The Company's lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.
Xequel Bio Technologies
Email Providers
Outlook
CMS
WordPress.org
Hosted Forms
Gravity Forms
Fonts
Google Font API
Other
Microsoft Office 365
Hosting
Google Cloud Hosting